About this episode

The episode discusses the financial challenges faced by individuals living with hepatitis B in the U.S. and features insights from Carl Schmid on treatment accessibility.

In this episode, Bright and Anousha chat with Carl Schmid, Executive Director of the HIV+Hepatitis Policy Institute, about the financial challenges people living with hepatitis B face in the U.S., including high medication costs, insurance barriers, and the ongoing struggle to access affordable, life-saving treatment. Note: Carl also shared an important update that at least one widely used hepatitis B medication is now available through Trump Rx for about $20 per month, offering a poten...

Explore listener stats, chart rankings, contacts and more on the B Heppy podcast page.